News Agency
Men's Weekly

280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

  • Written by PR Newswire

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280Bio is a wholly owned subsidiary of Shanghai Yingli...

Read more: 280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in...

Understanding K1042 Steel Plate And Where It Fits In Industrial Projects

The k1042 steel plate grade is often chosen when strength, consistency, and dependable performance are essential. In industrial and construction environments, material selection is rarely about appearance alone. It is about how steel behaves under load, how it responds to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion